High-Throughput Lead Finding and Optimisation for GPCR Targets

Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2006/2)


Driven by past successes and the detailed knowledge of signalling cascades and physiological processes, G-protein-coupled receptors are taking a prominent place in the portfolios of many pharmaceutical companies. To successfully address this target class, scientists need not only a good understanding of the specific receptor under investigation, but also the right tools from assay technology, reagent production to a hit-to-lead process that acknowledges the importance of parameters beyond potency and embraces the gain in knowledge of the last decade. This manuscripts attempts to summarise some of the changes and progress made across the pharmaceutical industry to design an efficient and effective strategy for finding and optimising small molecules modulating the activity of GPCRs.


Lead Optimisation Lead Finding Biological Screening Lead Selection Assay Technology 


  1. Abad-Zapatero C and Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. DDT 10:464–469PubMedGoogle Scholar
  2. Alanine A, Nettekoven M, Roberts E, Thomas AW (2003) Lead generation – enhancing the success of drug discovery by investing in the hit to lead process. Comb Chem High Through Screen 6:51–66Google Scholar
  3. Austen M, Dohrmann C (2005) Phenotype-first screening for the identification of novel drug targets. DDT 10:275–282PubMedGoogle Scholar
  4. Barak LS, Ferguson SSG, Zhang J, Caron MG (1997) A beta-arrestin green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem 272:27497–27500CrossRefPubMedGoogle Scholar
  5. Beaumont K, Schmid E and Smith DA (2005) Oral delivery of G protein-coupled receptor modulators: an explanation for the observed class difference. Bioorg Med Chem Lett 15:3658–3664CrossRefPubMedGoogle Scholar
  6. Bockaert J, Fagni L, Dumuis A, Marin P (2004) GPCR-interacting proteins (GIP). Pharmacol Ther 103:203–221CrossRefPubMedGoogle Scholar
  7. Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Zhengyin Y (2001) The New Pre-preclinical paradigm: compound optimisation in early and late phase drug discovery. Curr Top Med Chem 1:353–366CrossRefPubMedGoogle Scholar
  8. Carrithers MD, Marotti LA, Yoshimura A, Lerner MR (1999) A melanophore–based screening assay for Erythropoietin receptors. J Biomol Screen 4:9–14CrossRefPubMedGoogle Scholar
  9. Clemons PA (2004) Complex phenotypic assays in high-throughput screening. Curr Opin Chem Biol 8:334–338CrossRefPubMedGoogle Scholar
  10. Davis AM, Keeling DJ, Steele J, Tomkinson NP, Tinker AC (2005) Components of successful lead generation. Curr Topic Med Chem 5:421–439CrossRefGoogle Scholar
  11. Di L, Kerns EH (2003) Profiling dug-like properties in discovery research. Curr Opin Chem Biol 7:402–408CrossRefPubMedGoogle Scholar
  12. Fredriksson R, Schiöth HB (2005) The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharm 67:1414–1425CrossRefGoogle Scholar
  13. Glasel JA (2004) Emerging concepts in GPCR research and their implications for drug discovery. Decision Res www.decisionresources.com. Cited 26 November 2006Google Scholar
  14. Grånäs C, Lundholt BK, Heydorn A, Linde V, Pedersen HC, Krog-Jensen C, Rosenkilde MM, Pagliaro L (2005) High content screening for G protein-coupled receptors using cell-based protein translocation assays. Comb Chem High Throughput Screen 8:301–319CrossRefPubMedGoogle Scholar
  15. Gribbon P, Sewing A (2003) Fluorescence readouts in high throughput screening: no gain without pain? DDT 8:1035–1043PubMedGoogle Scholar
  16. Gribbon P, Sewing A (2005) High-throughput drug discovery: what can we expect from HTS? DDT 10:17–22PubMedGoogle Scholar
  17. Giuliano KA, Haskins JR, Taylor DL (2003) Advances in high content screening for drug discovery. Assay Drug Dev Technol 1:565–577CrossRefPubMedGoogle Scholar
  18. Hann MM, Oprea TI (2004) Pursuing the lead likeness concept in pharmaceutical research. Curr Opin Chem Biol 8:255–263CrossRefPubMedGoogle Scholar
  19. Hefti E, Bolten BM (2000) Advances in high throughput screening – do they lead to new drugs? Decision Resources, October 2003, www.decisionresources.com. Cited 26 November 2006Google Scholar
  20. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Disc 1:727–730CrossRefGoogle Scholar
  21. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. DDT 9:430–431PubMedGoogle Scholar
  22. Jäger S, Brand L, Eggeling C (2003) New fluorescence techniques for high-throughput drug discovery. Curr Pharm Biotechnol 4:463–476CrossRefPubMedGoogle Scholar
  23. Klabunde T, Hessler G (2002) Drug design strategies for targeting G-protein-coupled receptors. Chem Bio Chem 3:928–944PubMedGoogle Scholar
  24. Klumpp M, Scheel, Lopez-Calle, Busch, Murray J, Pope AJ (2001) Ligand binding to transmembrane receptors on intact cells or membrane vesicles measured in a homogeneous 1-microliter assay format. J Biomol Screen 6:159–170CrossRefPubMedGoogle Scholar
  25. Kunapili P, Zheng W, Weber M, Solly K, Mull R, Platchek M, Cong M, Zhong Z, Strulovici B (2005) Application of division arrest technology to cell-based HTS: comparison with frozen and fresh cells. Assay Drug Dev Techn 3:17–26CrossRefGoogle Scholar
  26. Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) The maximal affinity of ligands. Proc Acad Nat Sci USA 96:9997–10002CrossRefGoogle Scholar
  27. Lipinski C, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25CrossRefGoogle Scholar
  28. May LT, Avlani VA, Sexton PM, Christopulus A (2004) Allosteric modulation of G protein-coupled receptors. Curr Pharm Des 10:2003–2013CrossRefPubMedGoogle Scholar
  29. Milligan G (2003) High-content assays for ligand regulation of G-protein coupled receptors. DDT 8:579–585PubMedGoogle Scholar
  30. Milligan G (2004) G protein-coupled receptor dimerisation: function and ligand pharmacology. Mol Pharmacol 66:1–7CrossRefPubMedGoogle Scholar
  31. Minic J, Sautel M, Salesse R, Pajot-Augy E (2005) Yeast system as a screening tool for pharmaceutical assessment of G protein-coupled receptors. Curr Med Chem 12:961–969CrossRefPubMedGoogle Scholar
  32. Moore K, Rees S (2001) Cell-based versus isolated target screening: how lucky do you feel? J Biomol Screen 6:69–74PubMedGoogle Scholar
  33. Nambi P, Aiyar N (2003) G protein-coupled receptors in drug discovery. Ass Drug Dev Tech 1:305–310CrossRefGoogle Scholar
  34. Nowlin D, Bingham P, Berridge A, Gribbon P, Laflin P, Sewing A (2006) Analysing the output from primary screening. Com Chem High Trough Screen 9:331–337CrossRefGoogle Scholar
  35. Peakman T, Franks S, White C, Beggs M (2003) Delivering the power of discovery in large pharmaceutical organisations. DDT 8:203–211PubMedGoogle Scholar
  36. Presland J (2005) Identifying novel modulators of G protein-coupled receptors via interaction at allosteric sites. Curr Opin Drug Disc Dev 8:567–576Google Scholar
  37. Rüdiger M, Haupts U, Moore KJ, Pope AJ (2001) Single-molecule detection technologies in miniaturised high throughput screening: binding assays for G protein-coupled receptors using fluorescence intensity distribution analysis and fluorescence aninsotropy. J Biomol Screen 6:29–37PubMedGoogle Scholar
  38. Sams-Dodd F (2005) Target-based drug discovery: Is something wrong? DDT 10:139–147PubMedGoogle Scholar
  39. Thomsen WJ, Gatlin J, Unett DJ, Behan DP (2004) Developing functional GPCR screens. Curr Drug Disc 1:13–18CrossRefGoogle Scholar
  40. Thomsen W, Frazer J, Unett D (2005) Functional assays for screening GPCR targets. Curr Opin Biotech 16:655–665PubMedGoogle Scholar
  41. Wakatsuki T, Fee JA, Elson EL (2004) Phenotypic screening for pharmaceuticals using tissue constructs. Curr Pharm Biotech 5:181–189CrossRefGoogle Scholar
  42. Williams C (2004) cAMP detection methods in HTS: selecting the best from the rest. Nat Rev Drug Discov 3:125–135CrossRefPubMedGoogle Scholar
  43. Williams C, Sewing A (2005) G-protein-coupled receptor assays: to measure affinity or efficacy, that is the question. Comb Chem High Through Screen 8:285–292CrossRefGoogle Scholar
  44. Wintner EA, Moallemi CC (2000) Quantized surface complementarity diversity (QSCD): a model based small molecule-target complementarity. J Med Chem 43:1993–2006CrossRefPubMedGoogle Scholar
  45. Young SS, Lam RLH, Welch WJ (2002) Initial compound selection for sequential screening. Curr Opin Drug Disc Dev 5:422–427Google Scholar
  46. Zuck P, Murray EM, Stec E, Grobler JA, Simon AJ, Strulovici B, Inglese J, Flores OA, Ferrer M (2004) A cell-based b-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. Ana Biochem 334:344–355CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Primary Pharmacology Group, Pfizer PDGRDSandwichUK

Personalised recommendations